Distribution of HLA-A, -B and -DRB1 alleles in patients with sudden sensorineural hearing loss.
This study was performed to investigate the association between human leukocyte antigen (HLA) and susceptibility to sudden sensorineural hearing loss in the Korean population. HLA-A and HLA-B typing using a standard microlymphocytotoxicity technique and HLA-DRB1 genotyping were performed in 35 patients with sudden sensorineural hearing loss and in 206 healthy controls. Prednisone (usual dose 60 mg/day) was administered for 6 days and tapered for an additional 4-6 days. Both initial hearing levels at the onset of deafness and final hearing levels after treatment were examined and evaluated for association with HLA alleles. The frequency of HLA-DRB1*14 was increased in patients with sudden sensorineural hearing loss compared with controls (relative risk [RR] = 2.7, p = 0.016). The frequencies of HLA-A2, -A31, -B52, -B61, -DRB1*04, -DRB1*11 and -DRB1*12 were slightly higher than in the controls, but did not reach statistical significance. When an association between the treatment results and HLA alleles was also evaluated, the frequency of HLA-DRB1*04 was found to be increased in the patients who did not respond to steroid treatment compared with both patients who responded well to steroid (50%, vs 16%, p = 0.034) and controls (RR = 3.0, p = 0.046). These results suggest that there is an association between HLA-DRB1*14 and disease susceptibility and that the presence of HLA-DRB1*04 may be an useful marker for predicting a poor prognosis in Korean patients with sudden sensorineural hearing loss.
Yeo
S W
SW
Department of Otolaryngology, Kangnam St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, South Korea. swyeo@cmc.cuk.ac.kr
Chang
K H
KH
Suh
B D
BD
Kim
T G
TG
Han
H
H
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone / Q000379:methods; D005260:Female; D005787:Gene Frequency / Q000235:genetics* / Q000276:immunology*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015234:HLA-A Antigens / Q000235:genetics* / Q000276:immunology*; D015235:HLA-B Antigens / Q000235:genetics* / Q000276:immunology*; D006684:HLA-DR Antigens / Q000235:genetics* / Q000276:immunology*; D059811:HLA-DRB1 Chains; D003639:Hearing Loss, Sudden / Q000175:diagnosis / Q000188:drug therapy / Q000208:ethnology / Q000235:genetics / Q000276:immunology; D006801:Humans; D007723:Korea / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D020127:Recovery of Function; D012720:Severity of Illness Index
D000893:Anti-Inflammatory Agents; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D011241:Prednisone